-
Ana Martins wrote a new post 1 month ago
"DIGESTIVE CANCER – CURRENT AND FUTURE APPROACHES FOCUSED ON PREVENTION" Highlights the Importance of Awareness and Prevention On 26 February, the Main Auditorium of the Portuguese Oncology Institute of Porto (IPO Porto) was the stage for the event “Digestive Cancer – […]
-
Ana Martins wrote a new post 2 months, 1 week ago
Gemcitabine Plus Paclitaxel vs Gemcitabine Alone after FOLFIRINOX in Metastatic Pancreatic Cancer GEMPAX was an open-label (both researchers and patients know which treatment is being administered), randomised (randomly assigns participants i […]
-
Ana Martins changed their profile picture 6 months ago
-
Ana Martins wrote a new post 6 months ago
F2F Consortium Meeting in Madrid The GUIDE.MRD (Guiding multi-modal therapies against MRD by liquid biopsies) consortium partners met for the first face-to-face annual meeting […]
-
Ana Martins wrote a new post 9 months, 1 week ago
Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX […]
-
Ana Martins wrote a new post 9 months, 1 week ago
DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large […]
-
Ana Martins wrote a new post 9 months, 1 week ago
Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreatic c […]